Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26F9V67
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $20,323
Award facts
- Contract value 100% obligated
- $20,322.96 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
This delivery order, awarded January 8, 2026, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, covers the supply of Dupixent 300 mg/2 ml pen injectors with a firm fixed price ceiling value of $20,322.96 and an ultimate completion date of January 9, 2026. The award represents a non-competed delivery order under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, supplying brand-name and generic medications, vaccines, and medical devices across multiple therapeutic domains to military and veteran healthcare systems.
Dupixent is a specialized biologic treatment used for conditions including eczema, asthma, and chronic rhinosinusitis, representing the type of specialty pharmaceutical product included within the company's comprehensive global pharmaceutical support vehicle. This delivery order reflects the routine procurement of essential medications through the established DLA Medical Supply Chain, which enables efficient fulfillment of healthcare needs across military treatment facilities and related federal medical institutions. The parent organization, Cencora, Inc., also maintains a significant IDC with DLA Troop Support Medical valued at $999,999,999.00 through December 2031, further demonstrating the company's role as a primary pharmaceutical vendor to the Department of Defense healthcare enterprise.
Quick answers
Who was awarded contract SPE2DR26F9V67?
SPE2DR26F9V67 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 8, 2026.
How much is contract SPE2DR26F9V67 worth?
The government has obligated $20,323 on SPE2DR26F9V67.
Is contract SPE2DR26F9V67 an order under another contract?
Yes. SPE2DR26F9V67 is a delivery order under SPE2DR25D3103, an indefinite delivery contract.
Was contract SPE2DR26F9V67 competed?
The extent of competition for SPE2DR26F9V67 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award